Fred Alger Management’s Mersana Therapeutics MRSN Stock Holding History

Fred Alger Management’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-15,138	Closed	-$2.22M	–	552
2022 Q4	$2.22M	Buy	15,138 +182	+1%	+$30.8K	0.01%	332
2022 Q3	$2.53M	Sell	14,956 -3,030	-17%	-$492K	0.01%	318
2022 Q2	$2.08M	Buy	17,986 +5,063	+39%	+$476K	0.01%	332
2022 Q1	$1.29M	Buy	12,923 +3,783	+41%	+$442K	﹤0.01%	368
2021 Q4	$1.42M	Buy	+9,140	New	+$1.78M	﹤0.01%	377

Other funds holding MRSN

OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return